🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million new cases annually. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Global Access

According to results published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The trial included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have voiced positive views. The availability of a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is considered essential to lessen the impact of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.